Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02303444 · ClinicalTrials.gov registry record

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

A clinical trial of Thyroid Neoplasms, sponsored by Bayer.

Completed
Registry status
667
Enrollment target
20
Study locations

NCT02303444 is a study of Thyroid Neoplasms that has completed, run by Bayer. The registered enrollment target is 667 participants, below the 744-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02303444, a study of Thyroid Neoplasms, has completed, sponsored by Bayer.

COMPLETED
Registry status
667 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

Conditions Studied

Thyroid Neoplasms

Interventions

  • DRUG Sorafenib (Nexavar, BAY43-9006)
  • DRUG Other Multikinase inhibitors

Study Locations (20)

Other

  • - Multiple Locations
  • - Multiple Locations
  • - Multiple Locations
  • - Multiple Locations

California

  • - Los Angeles
  • - Torrance

Alabama

  • - Birmingham

Colorado

  • - Aurora

District of Columbia

  • - Washington D.C.

Florida

  • - Plantation

Georgia

  • - Atlanta

Hawaii

  • - Honolulu

Trial Details

FieldValue
Enrollment Target 667 participants
Start Date 2015-04-08
Est. Completion 2020-07-24

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02303444

The ClinicalTrials.gov registry entry for NCT02303444 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 744-participant average among 7 other Thyroid Neoplasms trials with a reported enrollment target (10% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thyroid Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.

NCT02303444 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT02303444 about?

NCT02303444 is a clinical study titled "An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors". The purpose of the study was to assess the use of Multikinase Inhibitors (MKIs) in the treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAI) who do not have any symptoms.

What is the current status of trial NCT02303444?

This trial is currently completed. The enrollment target is 667 participants. The study started on 2015-04-08. Estimated completion is 2020-07-24.

What conditions does trial NCT02303444 study?

This clinical trial studies the following conditions: Thyroid Neoplasms.

What interventions are being tested in trial NCT02303444?

The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG), Other Multikinase inhibitors (DRUG).

Who is sponsoring clinical trial NCT02303444?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02303444 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Neoplasms

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.